Uganda’s National Drug Authority (NDA) has officially approved Lenacapavir, a long-acting injectable drug used for HIV prevention (PrEP), marking a major milestone in the country’s fight against HIV/AIDS.
Lenacapavir, manufactured by Gilead Sciences, a United States-based pharmaceutical company, is administered just twice a year, offering protection against HIV infection for six months per dose. This makes it the first HIV prevention method of its kind, significantly reducing the burden of daily pill-taking associated with traditional oral PrEP.
A Game-Changer in HIV Prevention
Health experts have welcomed the approval as a game-changer, particularly for individuals at high risk of HIV infection. Daily oral PrEP has proven effective, but adherence remains a challenge for many due to stigma, forgetfulness, lifestyle factors, and limited access to health facilities. The twice-yearly injectable option is expected to greatly improve adherence, privacy, and convenience.
Clinical trials have shown Lenacapavir to be highly effective, offering near-complete protection against sexually acquired HIV when administered correctly. Its long-acting nature makes it especially suitable for young people, key populations, mobile communities, and those who struggle with daily medication routines.
Boost to Uganda’s HIV Response
Uganda continues to record new HIV infections each year despite progress in treatment and prevention. The introduction of Lenacapavir adds a powerful new tool to the national HIV prevention strategy, complementing existing options such as condoms, oral PrEP, and voluntary medical male circumcision.
Health authorities believe the injectable PrEP will help close prevention gaps, especially among populations that have been difficult to reach with current interventions.
Step Toward Ending AIDS by 2030
The approval aligns with Uganda’s commitment to ending AIDS as a public health threat by 2030, in line with global targets. Long-acting HIV prevention technologies like Lenacapavir are seen as critical innovations needed to dramatically reduce new infections over the next decade.
What Comes Next
Following regulatory approval, the Ministry of Health is expected to issue implementation guidelines, including eligibility criteria, rollout plans, health worker training, and integration into existing HIV prevention programs. Stakeholders have emphasized the need to ensure affordability, equitable access, and nationwide availability.
A New Era in Prevention
With this approval, Uganda joins a growing list of countries adopting next-generation HIV prevention solutions. Lenacapavir represents a major leap forward — offering hope, convenience, and renewed momentum in the fight to end HIV/AIDS.
